This episode covers the FDA’s premarket approval of Claire, the first AI-enabled imaging device for intraoperative breast cancer margin assessment, demonstrating eighty eight point one percent margin accuracy in pivotal trials and incorporating a predetermined change control plan for AI enhancements. We also review Ultrasound AI’s De Novo clearance for Delivery Date AI, a cloud-based system achieving zero point nine two R-squared accuracy in predicting delivery timing across over five thousand seven hundred patients, and PathAI’s Breakthrough Device Designation for PathAssist Derm, an adjunctive pathology tool addressing documented inter-observer concordance below fifty percent in diagnostically challenging melanocytic lesions. The briefing concludes with the FDA’s draft guidance establishing the plausible mechanism framework for individualized genetic therapies, formalizing evidentiary standards within existing statutory pathways and requiring single adequate and well-controlled investigations paired with confirmatory mechanistic data.
